MICHAEL VASCONCELLES - 29 Dec 2022 Form 4 Insider Report for ImmunoGen, Inc.

Role
EVP R&D & MEDICAL AFFAIRS
Signature
/s/ Renee Lentini, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
29 Dec 2022
Net transactions value
$0
Form type
4
Filing time
03 Jan 2023, 16:17:11 UTC
Previous filing
17 Aug 2022
Next filing
03 Jan 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IMGN Stock Option (Right to Buy) Award $0 +960,000 $0.000000 960,000 29 Dec 2022 Common Stock 960,000 $5.16 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These options vest over a four-year period, with 25% of the shares vesting on the one-year anniversary of the date of grant, and thereafter an additional 6.25% of the shares vesting on each succeeding quarterly anniversary of the date of grant.